Source comparison
Comparison Table: CJC-1295 Protocols Across Age Brackets
Before selecting a protocol, understanding how age-related physiology changes dosing requirements clarifies why one-size-fits-all approaches consistently underperform in older cohorts. | Age Bracket | CJC-1295 Dose | Frequency | Concurrent GHRP | Expected IGF-
This comparison does not assign a generated winner or score.
- Before selecting a protocol, understanding how age-related physiology changes dosing requirements clarifies why one-size-fits-all approaches consistently underperform in older cohorts.
- | Age Bracket | CJC-1295 Dose | Frequency | Concurrent GHRP | Expected IGF-1 Increase | Primary Limitation | Professional Assessment ||—|—|—|—|—|—|| 20–35 years | 200–300mcg | Once weekly | Optional | 60–100ng/mL | None. Pituitary function at peak | Standard protocol works as published; no age adjustment needed || 35–50 years | 200mcg | Once weekly | Recommended | 40–70ng/mL | Pulse frequency beginning to decline | GHRP co-administration improves consistency; weekly dosing still viable || 50–65 years | 100–200mcg | Twice weekly | Mandatory | 40–60ng/mL (with GHRP) | Reduced pulse amplitude and frequency; slower peptide clearance | Twice-weekly dosing + GHRP restores response to near-younger levels; weekly dosing alone underperforms || 65+ years | 100–150mcg | Twice weekly | Mandatory | 25–45ng/mL (with GHRP) | Hepatic IGF-1 synthesis capacity declines; insulin resistance more common | Even with dual-pathway stimulation, absolute IGF-1 ceiling is lower; metabolic optimization required f